- Home
- / Y-mAbs Therapeutics
Y-mAbs Therapeutics
Stock Price
$14.7
2024-10-29
Market Capitalization
$657 M
2024-10-29
Revenue
$87.7 M
FY, 2024
Y-mAbs Therapeutics Summary
Company Summary
- Overview
- Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets. The Company applies its antibody capabilities to create immunotherapies for cancer patients of all ages. Y-mAbs Therapeutics' mission is to develop better and safer antibody based pediatric oncology products addressing clear unmet medical needs.
- Type
- Public
- Status
- Active
- Founded
- 2014
- HQ
- New York, NY, US | view all locations
- Website
- https://www.ymabs.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
James I. Healy, Chairman of the Board of Directors
Vignesh Rajah, SVP, Chief Medical Officer
Steen Lisby, Chief Scientific Officer
LocationsView all
3 locations detected
New York, NY HQ
United States
230 Park Avenue, Suite 3350
Nutley, NJ
United States
111 Ideation Way, Basement Floor, Room C-008
Copenhagen
Denmark
Agern Allé 11, ground floor
Y-mAbs Therapeutics Financials
Summary Financials
- Revenue (Q2, 2025)
- $19.5M
- Gross profit (Q2, 2025)
- $16.9M
- Net income (Q2, 2025)
- ($3.2M)
- Cash (Q2, 2025)
- $62.3M
- EBIT (Q2, 2025)
- ($5.6M)
- Enterprise value
- $597.8M